| Linvoseltamab studied in …STUDIED_INderived20 of 20show fewer |
|---|
| → studied in | NCT07222761Phase 3 · recruiting A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · 20 trials list this drug (18 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07393282Phase 3 · recruiting A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) · 20 trials list this drug (18 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07609940Phase 4 · recruiting Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) · 20 trials list this drug (18 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07181941Phase 1/Phase 2 · recruiting Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07455851Phase 1/Phase 2 · recruiting A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07624513Phase 3 · not yet recruiting D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06292780Phase 1/Phase 2 · recruiting A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) · 20 trials list this drug (18 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06376526Phase 2 · recruiting IMMUNOPLANT for Newly Diagnosed Multiple Myeloma · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07009899Phase 2 · not yet recruiting BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06669247Phase 1/Phase 2 · recruiting A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05137054Phase 1 · recruiting A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06140524Phase 2 · recruiting A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma · 20 trials list this drug (18 active) | — | — | Smoldering Multiple Myeloma,Monoclonal Gammopathy of Undetermined Significance | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07428369Phase 2/Phase 3 · withdrawn A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05828511Phase 1/Phase 2 · recruiting A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03761108Phase 1/Phase 2 · recruiting Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05955508Phase 2 · active not recruiting A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma · 20 trials list this drug (18 active) | — | — | Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06932562Phase 3 · recruiting A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05730036Phase 3 · recruiting A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06910124Phase 2 · recruiting Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05164250approved for marketing Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM) · 20 trials list this drug (18 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |